The United States represents a mature and dominant country-level market for D-amino acids market, propelled by high pharmaceutical R&D expenditure, state-of-the-art bioprocessing facilities, and strong venture capital support for clinical-stage biotechnology firms. US biopharmaceutical companies actively incorporate specialized D-amino acid building blocks into custom peptide research,...